Jun 2026 (Q2 FY26) — Aug 12, 2026
Talphera Q2 FY26 — NEFRO CRRT Study 75% Enrolled, Expanded Market Opportunity for Nefamistat
Read the full callTalphera (TLPH) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Talphera earnings: last reported Wed, 12 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 0.00 | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. The year-earlier figure was zero or a loss, so no percentage is shown. | |
| Operating margin | Operating profit / revenue | Quarter to Jun 2026 | Not in the filed figures for the quarter to jun 2026. No older figure is substituted. | ||
| Net profit | -4.3 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$1.08 0.00% · $0
Performance +0.9% 1Y
1Y: $1.07 on 17 Oct 2025 → $1.08. High $1.47 (11 Aug 2026), low $0.72 (2 Apr 2026).
- Previous close
- $1.08
- 52-week range
- $0.72 – $1.47
- One year
- −6.09%
Overview
- Symbol
- TLPH
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Talphera earnings calls (TLPH)
Financials
What the filings say
Net profit, year on year: −24% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 4 | 3 | 3 | 4 | 3 | 3 | 4 | 4 |
| Operating profit | -4 | — | -3 | -4 | -3 | -3 | -4 | -4 |
| Operating margin | — | — | −10800.0% | — | −342200.0% | — | — | — |
| Other income | 0 | 1 | 0 | 0 | -1 | -0 | 1 | -0 |
| Interest | 0 | 0 | — | — | — | — | — | — |
| Profit before tax | -3 | — | — | — | — | — | — | — |
| Tax rate | 0.0% | — | — | — | — | — | — | — |
| Net profit | -3 | -2 | -3 | -3 | -4 | -4 | -3 | -4 |
| EPS ($ per share) | -0.13 | — | -0.10 | -0.10 | -0.11 | — | -0.04 | -0.06 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -345 | -398 | -438 | -474 | -426 | -444 | -457 | -472 |
| Total liabilities | 116 | 133 | 122 | 114 | 26 | 6 | 10 | 13 |
| Fixed assets | 11 | 15 | 16 | 16 | 10 | — | — | — |
| Investments | 18 | 51 | 16 | 39 | 0 | 4 | 0 | 14 |
| Total assets | 121 | 91 | 66 | 78 | 47 | 20 | 18 | 30 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -29 | -51 | -39 | -30 | -28 | -17 | -13 | -11 |
| Cash from investing | -11 | -37 | 34 | -26 | 36 | -1 | 4 | -14 |
| Cash from financing | 75 | 14 | 17 | 42 | -1 | 3 | 12 | 23 |
| Net cash flow | 35 | -73 | 13 | -15 | 8 | -15 | 3 | -3 |
| Capital expenditure | -1 | -3 | -2 | -2 | -0 | -0 | 0 | — |
| Free cash flow | -30 | -55 | -40 | -32 | -29 | -18 | -13 | — |
Insider filings
29 filings between Oct 23, 2025 and Jun 22, 2026.
Open market
decisions to buy or sellPurchases
$304.0K
5 purchases by 4 insiders
Sales
None
No insider sold shares.
Compensation
not trading decisions- 13
- Award — granted as compensation
- 11
- Tax withheld — shares kept back by the company to cover tax
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Angotti Vincent J. | $210.6K | — | Mar 13, 2026 |
| ASADORIAN RAFFI | $36.6K | — | Feb 12, 2026 |
| Dasu Badri N | $28.4K | — | Feb 12, 2026 |
| Aslam Shakil | $28.4K | — | Feb 12, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Jun 22, 2026 | ADAMS ADRIAN Director | Award | 5,100 | $0 |
| Jun 22, 2026 | HOFFMAN STEPHEN J Director | Award | 5,100 | $0 |
| Jun 22, 2026 | Broadfoot Jill Marie Director | Award | 5,100 | $0 |
| Jun 22, 2026 | WAN MARK A Director | Award | 5,100 | $0 |
| Jun 22, 2026 | Todisco Joseph Director | Award | 5,100 | $0 |
| Jun 22, 2026 | Bozilenko Marina Director | Award | 5,100 | $0 |
| Jun 22, 2026 | JAIN ABHINAV Director | Award | 5,100 | $0 |
| May 20, 2026 | Aslam Shakil Chief Medical Officer | Tax withheld | 4,518 | $3.7K |
| Apr 2, 2026 | Aslam Shakil Chief Medical Officer | Tax withheld | 2,118 | $1.5K |
| Apr 2, 2026 | Dasu Badri N Chief Engineering Officer | Tax withheld | 2,444 | $1.8K |
| Apr 2, 2026 | ASADORIAN RAFFI Chief Financial Officer | Tax withheld | 2,444 | $1.8K |
| Apr 2, 2026 | Angotti Vincent J. CHIEF EXECUTIVE OFFICER | Tax withheld | 9,938 | $7.2K |
| Mar 13, 2026 | Angotti Vincent J. CHIEF EXECUTIVE OFFICER | Purchase | 213,310 | $125.0K |
| Feb 14, 2026 | Dasu Badri N Chief Engineering Officer | Tax withheld | 2,346 | $1.9K |
| Feb 14, 2026 | Angotti Vincent J. CHIEF EXECUTIVE OFFICER | Tax withheld | 9,559 | $7.6K |
| Feb 14, 2026 | ASADORIAN RAFFI Chief Financial Officer | Tax withheld | 2,933 | $2.3K |
| Feb 12, 2026 | Aslam Shakil Chief Medical Officer | Purchase | 35,000 | $28.4K |
| Feb 12, 2026 | Dasu Badri N Chief Engineering Officer | Purchase | 35,000 | $28.4K |
| Feb 12, 2026 | ASADORIAN RAFFI Chief Financial Officer | Purchase | 45,000 | $36.6K |
| Feb 12, 2026 | Angotti Vincent J. CHIEF EXECUTIVE OFFICER | Purchase | 105,364 | $85.6K |
| Feb 10, 2026 | ASADORIAN RAFFI Chief Financial Officer | Tax withheld | 958 | $801 |
| Feb 10, 2026 | Dasu Badri N Chief Engineering Officer | Tax withheld | 781 | $653 |
| Feb 10, 2026 | Angotti Vincent J. CHIEF EXECUTIVE OFFICER | Tax withheld | 3,179 | $2.7K |
| Oct 23, 2025 | HOFFMAN STEPHEN J Director | Award | 4,267 | $0 |
| Oct 23, 2025 | Broadfoot Jill Marie Director | Award | 4,267 | $0 |
| Oct 23, 2025 | Bozilenko Marina Director | Award | 4,267 | $0 |
| Oct 23, 2025 | WAN MARK A Director | Award | 4,267 | $0 |
| Oct 23, 2025 | ADAMS ADRIAN Director | Award | 4,267 | $0 |
| Oct 23, 2025 | JAIN ABHINAV Director | Award | 4,267 | $0 |
| Oct 15, 2025 | Todisco Joseph Director | Award | 6,397 | $0 |
| May 20, 2025 | Aslam Shakil Chief Medical Officer | Tax withheld | 4,517 | $2.3K |
| Apr 2, 2025 | Angotti Vincent J. CHIEF EXECUTIVE OFFICER | Purchase | 213,310 | $125.0K |
| Apr 2, 2025 | Angotti Vincent J. CHIEF EXECUTIVE OFFICER | Award | 61,000 | $0 |
| Apr 2, 2025 | ASADORIAN RAFFI Chief Financial Officer | Award | 15,000 | $0 |
| Apr 2, 2025 | Dasu Badri N Chief Engineering Officer | Award | 15,000 | $0 |
| Apr 2, 2025 | Aslam Shakil Chief Medical Officer | Award | 15,000 | $0 |
| Feb 14, 2025 | Dasu Badri N Chief Engineering Officer | Tax withheld | 2,644 | $1.8K |
| Feb 14, 2025 | Angotti Vincent J. CHIEF EXECUTIVE OFFICER | Tax withheld | 10,575 | $7.1K |
| Feb 14, 2025 | ASADORIAN RAFFI Chief Financial Officer | Tax withheld | 3,245 | $2.2K |
| Feb 11, 2025 | Angotti Vincent J. CHIEF EXECUTIVE OFFICER | Tax withheld | 3,517 | $2.2K |
| Feb 11, 2025 | Dasu Badri N Chief Engineering Officer | Tax withheld | 880 | $546 |
| Feb 11, 2025 | ASADORIAN RAFFI Chief Financial Officer | Tax withheld | 1,060 | $657 |
| Feb 10, 2025 | Dasu Badri N Chief Engineering Officer | Tax withheld | 879 | $554 |
| Feb 10, 2025 | ASADORIAN RAFFI Chief Financial Officer | Tax withheld | 1,059 | $667 |
| Feb 10, 2025 | Angotti Vincent J. CHIEF EXECUTIVE OFFICER | Tax withheld | 3,515 | $2.2K |
| Dec 5, 2024 | Angotti Vincent J. CHIEF EXECUTIVE OFFICER | Purchase | 5,000 | $3.2K |
| Dec 2, 2024 | ASADORIAN RAFFI Chief Financial Officer | Sale | 155 | $119 |
| Nov 27, 2024 | Angotti Vincent J. CHIEF EXECUTIVE OFFICER | Purchase | 5,000 | $3.6K |
| Aug 30, 2024 | Angotti Vincent J. CHIEF EXECUTIVE OFFICER | Purchase | 7,260 | $7.6K |
| Jun 14, 2024 | Aslam Shakil Chief Medical Officer | Purchase | 5,000 | $5.4K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for TALPHERA, INC.
Free account. Everything above stays public.
Write why you follow TALPHERA, INC. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading